Year-end Sale % OFF 
Abstract
The 1st line treatment of metastatic renal cell carcinoma (mRCC) is either immuno-oncology drug (IO) with IO or IO + vascular endothelial growth factor - tyrosine kinase inhibitors (VEGF-TKIs). At progression, the 2nd line options are lenvatinib + everolimus (L+E) or cabozantinib which is based on older data from 1st line TKI era. The best treatment for patients who progress on 1st line IO combination is not clear. In this study, we report the efficacy and safety of (L+E) in patients with mRCC who progressed on IO + TKI combination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
